The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome

Background Rasburicase is a recombinant urate oxidase enzyme used for the treatment and prevention of tumor lysis syndrome. Our objective was to assess the efficacy of indication-based, low-dose rasburicase administration compared to the Food and Drug Administration-approved weight-based dosing. Met...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of oncology pharmacy practice 2019-04, Vol.25 (3), p.577-583
Hauptverfasser:	Boutin, Alyssa, Blackman, Alison, O’Sullivan, David M, Forcello, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Cost control Dosage Drug dosages FDA approval Health care facilities Indication Lysis Patients Urate oxidase Uric acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!